Who Paid My Doc
Matthew Quirk
Vascular & Interventional Radiology Los Angeles, CA Medical Doctor
NPI 1528324522 CMS profile 1384283
757 Westwood Plz Ste 1638, Los Angeles, CA 90095
General payments
$16,008
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$3,620
Through program year 2025, Matthew Quirk of Los Angeles, CA is reported in the CMS Open Payments database as having received $16,008 across 96 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,620 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 83rd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $678 | 8 | |
| 2024 | General | $1,282 | 11 | |
| 2023 | General | $1,155 | 16 | |
| 2022 | General | $11,101 | 36 | |
| 2021 | General | $665 | 9 | |
| 2020 | General | $179 | 4 | |
| 2019 | General | $947 | 12 |
Beside peers
- Matthew Quirk
- Vascular & Interventional Radiology median
- Middle half of Vascular & Interventional Radiology
- National median
In program year 2025, general payments to Matthew Quirk were reported at $678. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.
Show as a table
| Year | Matthew Quirk | Vascular & Interventional Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $947 | $422 | $125–$1,555 | $163 |
| 2020 | $179 | $200 | $68–$652 | $114 |
| 2021 | $665 | $280 | $99–$866 | $132 |
| 2022 | $11,101 | $433 | $137–$1,497 | $149 |
| 2023 | $1,155 | $506 | $152–$2,019 | $160 |
| 2024 | $1,282 | $556 | $175–$1,930 | $164 |
| 2025 | $678 | $534 | $166–$2,075 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
17
Drug cost
$62
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ciprofloxacin Hcl | Generic | 17 | $62 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 155 billing codesPaid by Medicare
$436,975
Medicare patients
1,076
Services billed
34,579
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 50% | |
| Ischemic heart disease | 41% | |
| Cancer | 40% | |
| Diabetes | 36% | |
| Chronic kidney disease | 35% | |
| Heart failure | 23% | |
| Depression | 23% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, gadoxetate disodium, 1 ml A9581 | Office | 46 | 550 | $6,355 |
| Injection, gadobutrol, 0.1 ml A9585 | Office | 226 | 20,350 | $4,953 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 108 | 11,320 | $1,167 |
| Injection, fentanyl citrate, 0.1 mg J3010 | Office | 35 | 42 | $31 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 43 | 96 | $11 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
96 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Vascular & Interventional Radiology in California
Mahmood Razavi
Vascular & Interventional Radiology · Orange, CA
Keith Terasaki
Vascular & Interventional Radiology · Los Angeles, CA
Bart Dolmatch
Vascular & Interventional Radiology · Mountain View, CA
Edward Lee
Vascular & Interventional Radiology · Los Angeles, CA
Alexander Misono
Vascular & Interventional Radiology · Newport Beach, CA
Kevin Burns
Vascular & Interventional Radiology · Orange, CA
Related records
Vascular & Interventional Radiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Vascular & Interventional Radiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.